Indian medical devices: what India makes, and what's priced in

The 60-second view

India’s medical-device story is a real import-substitution story, but it sits mostly in plastic and steel disposables and mid-technology assembly, the margin pools are at the maker and the hospital, and the only scaled listed pure-play, Poly Medicure, is priced for its best case.

It is written as an investment-committee memo: what must be true, what is priced in, and what would prove it wrong.

What India can and cannot make explains most of the rest. It makes IV sets, cannulas, syringes, needles, blood bags, gloves and labware competitively, because the value sits in tooling, automated lines and sterile supply chains rather than in the polymer. It assembles stents, dialysers, ultrasound and X-ray systems, but imports what sits underneath: medical-grade resins, specialty alloys, membranes, X-ray tubes and detectors, sensors, semiconductors and magnets. Imports were about $8.8 billion against $4 billion of exports in FY25. The second-order consequence is that the listed winners today are the integrated assemblers, not the suppliers beneath them, and that in my reading a margin cap on the channel would reach makers last.

The committee question is therefore two questions. Is the sector worth owning? The runway for import substitution says yes, and the policy and demand drivers back it. Is the stock worth its price? For Poly the price leaves no cushion: it asks for roughly twice the growth I would underwrite, or a margin double today’s, and it gives little visible discount to the policy, tariff and dumping risks listed above. The kill criteria for the sector thesis and for the Poly case are in the final section.

Products and how they are made

Indian makers are strongest where a product is moulded, extruded or assembled from imported plastic and steel inputs, and weakest where it needs a membrane, a precision sensor, a magnet or a specialty chemical.

Sources: Medikabazaar (infusion-set anatomy), HDFC Securities initiation on Poly Medicure, May 2023 (raw-material imports, patents, dialysers; FY22-23 data), HMD needle brochure, SMT summary (FY26 purchases, market share), IIT hollow-fibre work, knee-implant cap, Aug 2017, Department of Pharmaceuticals task force, Business Today, Aug 2026, Fischer MRI. The process descriptions are general industry practice, not company-specific disclosures; where I could not find an import share (medical-grade resins, hypodermic tube, membranes) I say so rather than estimate.

Two things to take from this table. First, the moat in disposables is not the polymer: it is the mould tool room, the automated line and the sterile, regulated supply chain, which is why a 340-patent maker earns 24% to 28% EBITDA while commodity syringe lines compete on price. Second, the same table shows where margins are capped: whoever supplies the resin, the membrane or the tube sets the cost floor, and in India that supplier is usually foreign.

India’s manufacturing capability map

India is a competitive maker of plastic and steel disposables, an assembler of most mid-technology devices, and a net importer of the components, membranes, sensors and magnets that sit underneath them: imports were about $8.8 billion against $4 billion of exports in FY25, and local content is only about 30%.

Sources: Business Today, Aug 2026, India Briefing, GrowthJockey: supply-chain tiers, GrowthJockey: import addiction, SMT summary. Tier placement of individual products is my synthesis of these sources; none gives a product-by-product import share.

What shapes the map:

• Concentrated import bill: imports span about 6,000 devices across 160 HS codes, and 40 codes account for roughly 85% of the bill. Localising a few dozen products would move the total.
• Cost structure works against assemblers: most devices carry 5% GST while many inputs and job work carry 18%; ASEAN goods enter at zero tariff and Chinese product is alleged to be routed through Malaysia and Vietnam; public tenders often pick the lowest bid.
• Policy is real but small against the gap: the PLI scheme covers 55 high-end devices with a 5% incentive on incremental sales for a five-year performance period (FY23 to FY27); 28 of 77 applications were approved and 22 projects have started, with Rs 12,344 cr of sales and Rs 5,869 cr of exports reported. Medical device parks add shared testing, calibration and EO sterilisation; reported counts differ (four operating parks in one source, nine named sites in another, including AMTZ at Visakhapatnam, Telangana, Oragadam in Tamil Nadu, Kerala, and the UP park near Noida).
• Government targets: import dependence below 40% and output of $30 billion by 2030 (cited by GrowthJockey); these are aims, not forecasts.
• The second-order point: a component maker needs volume to justify the capital, and that volume exists only if many assemblers buy locally; the reverse is also true. That is why clusters and procurement preference matter more than a single plant, and why the listed winners are today the integrated assemblers rather than the suppliers beneath them.

The value chain and where the margins lie

Margin follows scarcity: it sits with makers whose products need approvals and clinical evidence and with hospital billing, while the importer or distributor in between earns a thin 4% to 10%.

Start at the left. Components are the one stage where this note has no sourced margin, but it does have the dependence: Poly Medicure imported 60% to 70% of its raw materials in FY22-23 and SMT’s imports were 77% of its FY26 purchases, so part of the manufacturing margin is spent abroad before the product exists. At the manufacturer, margin tracks how hard the product is to copy. A maker of IV sets or syringes sells into a crowded field with little clinical lock-in; a maker of stents, cardiology devices or dialysers needs approvals and clinical evidence, which is what supports Poly’s 24% to 28% EBITDA and Medtronic’s 24.4% operating margin. Geography matters too: a 2023 HDFC Securities note put Poly’s domestic EBITDA margin at 18% to 20% against about 30% on exports. That is one older source I could not refresh, so read it as direction, not level.

Two readings survive the definitional mismatch. First, the distribution-type names with data earn single digits to about 10% (Meril India’s distribution arm 10.4%, Vasa Denticity 6.1%), and that thin margin has to fund inventory and receivables. Second, SMT at 14.1% sits far below the 27.1% global median even though it makes stents, so in my reading it is scale and product mix, not an Indian cost advantage, that sets a maker’s margin.

The largest spread has no audited margin attached to it. A Maharashtra price-monitoring survey of inpatient consumables found a standard IV infusion set bought at Rs 11.05 and billed at an MRP of Rs 325 (a 2,841% mark-up), a 10 ml syringe at Rs 6.75 against Rs 57.20 (747%) and a disposable mask at 153%. The industry body AiMeD cites cardiac catheters landed at Rs 1,500 to 2,000 against MRPs of Rs 7,000 to 11,000. That spread is why policy attention is moving to the channel: on 18 September the health minister asked the Department of Pharmaceuticals to evaluate trade-margin rationalisation, and a parliamentary committee suggested capping the landing-price-to-MRP gap at 20% (the article does not print the year, so I infer 2026). Precedents exist: stent and knee-implant price caps in 2017 and a 70% trade-margin cap on five device types in July 2021.

My inference, not a policy fact: if a cap is set at the first point of sale, the squeeze lands on importers, distributors and hospital billing, and a manufacturer selling at ex-factory prices is hit less directly. The second-order effect is the one to watch. A lower MRP ceiling removes the room that lets a hospital absorb a tender discount, so price pressure can travel back to the maker at the next tender, and makers of commodity consumables would feel it before makers of differentiated implants.

Sources: Mercer Capital (global median, data to 31 Mar 2026), Medtronic FY26 release, CARE Ratings on Meril Life Sciences India, Medical Buyer on the mark-up survey, Business Today, Apr 2026, IPO Watch on SMT, Poly Medicure Q1 FY27 slides, and Screener.in company pages (23 Oct 2026) for the listed names.

What will drive the next phase of growth

The next phase is driven more by import substitution, product-mix upgrades and exports than by the market simply getting bigger, which matters because published market-size forecasts imply growth anywhere from about 6% to about 27% a year.

Sources: IBEF, BusinessToday on hospital capex, India Briefing on PLI, SMT summary, Business Today, Aug 2026, Poly Medicure Q1 FY27 slides, Poly Medicure Q1 FY27 call (10 Aug 2026).

Three things follow. First, growth converts to profit only where the product has moved up the value ladder: Poly’s FY26 sales grew 12% but net profit fell 5%, and four of the original five proxies had lower profit on higher sales. Second, the fastest-growing lines (cardiology, structural heart, trauma) are the ones with the longest approval and clinical lead times, so growth arrives in steps tied to certifications rather than smoothly. Third, a market growing 15% to 20% with import substitution adds roughly 1.5 to 2 times that rate to a domestic maker’s addressable share, but only until local share reaches the ceiling set by the components India cannot yet make.

Indian versus global players

Indian makers compete on cost, regulated-market exports and bought capability in mid-complexity categories rather than on frontier technology, so the comparison with global leaders is best made category by category, not company against company.

Sources: Screener.in and the Poly Medicure Q1 FY27 slides; Mercer Capital (global medians, data to 31 Mar 2026); Medtronic FY26 release; iData Research on tariffs. Cross-currency comparisons use an illustrative Rs 85 per dollar and are orders of magnitude, not precise ratios.

The Indian edge is real but narrow. Single-use consumables (infusion sets, cannulas, syringes, blood bags) are high-volume, process-driven products where Indian cost levels and export approvals matter more than invention, and Indian Class-C devices are priced 10% to 40% below imports. That is where Poly built its position. The edge fades as the product gets harder: the advanced devices India makes locally are about a fifth of its Class-C demand, imaging is mostly imported, and a 1.6% R&D budget cannot fund a frontier pipeline. Buying capability is the shortcut Poly has taken, with PendraCare (Netherlands, interventional cardiology catheters, EUR 18.8 million for 90%) and Citieffe (Italy, trauma implants, about EUR 31 million) in 2025.

Second-order read: the global leaders are not the only competitors. Chinese makers set the price in commodity lines (Poly’s renal sales fell 3.8% on Chinese pricing), and unlisted Indian champions such as Meril compete in the same mid-complexity categories where SMT and Poly are trying to move up. So an Indian listed maker’s real contest is a price war at the bottom and a certification race at the top, and the valuation premium of about two times the global multiple pays for winning the second while surviving the first.

Listed proxies to track

Poly Medicure is the only scaled, liquid listed pure-play; every other name is a small cap, an SME listing or a mixed-model company, and trailing P/Es run from 22x to 135x.

Source: Screener.in company pages (consolidated, 23 Oct 2026 close), copied as displayed. Molbio’s own page shows P/E 57.2; other pages’ peer tables showed 65.8. SMT’s Screener sales of Rs 1,210 cr differ from Rs 1,219 cr in its IPO notes. Screener’s EV/EBITDA includes other income. Prevest Denpro returned a 404 and is dropped; Shree Pacetronix and Centennial Surgical were not checked; Meril and Healthium are unlisted.

How to use the list:

• Bellwether: Poly Medicure tells you whether Indian consumables makers can grow revenue and hold margin at the same time.
• Import-substitution test: SMT is the first listed stent and structural-heart maker; its first results show whether a 14% margin business deserves a 59x multiple.
• Demand check: Apollo’s bed additions drive consumable volumes for the whole set.
• Cautionary tale: Tarsons shows what happens when revenue stalls and depreciation and debt stay: profit fell about 86% in four years.

Key risks and threats to the story

The most probable source of near-term losses is not demand but price: a trade-margin cap, Chinese dumping, a tariff, or a de-rating of premium multiples; the structural risk is that India stays an assembler of imported components.

Source: Screener.in, the sources linked above and the Poly Medicure Q1 FY27 call (10 Aug 2026). Likelihood and impact are my judgement, not measured probabilities.

Valuations: what’s priced in, and what isn’t

At Rs 1,444 Poly Medicure’s price already pays for Vision 2030 and a premium multiple that lasts, while it gives little visible credit for the channel-margin, tariff and dumping risks; the smaller proxies need margins well above today’s to justify their prices.

A reverse DCF solves for what each price needs (growth, margin or discount rate) without producing a fair value. A return-hurdle grid asks what earnings growth and exit multiple a target return needs. Peer multiples show where each stock sits against the group and the global median. A sum of the parts for Poly Medicure prices its segments separately. Every forward number is my assumption and is marked (E).

What the price of each proxy needs

Each row holds the stylised reverse DCF to the same shape: revenue compounds at a constant 15% or 20% for ten years, the margin stays constant, tax is 25%, cost of capital runs from 12.5% (Poly) to 14.5% (smallest names) by size, terminal growth is 5.5%, and reinvestment equals D&A plus half of incremental revenue plus working capital of 22% of incremental revenue. The bar is the margin that makes the discounted cash flows equal today’s enterprise value. It tests plausibility; it does not forecast.

Poly needs 40% to 50% against 23% earned, and the global device median is 27.1%, so the price needs a margin that few device makers anywhere earn. Tarsons and Molbio need even more, and Tarsons’ depreciation of 24% of sales is a large part of why. Only Q-Line Biotech sits within a few points of its required margin, and it is a small SME-listed name with thin data. The stocks that look cheapest on EV/Sales (Vasa, Laxmi, SMT) are not cheap on this test, because their current margins are far below what the price needs.

Enterprise values are from Screener.in at the 23 Oct 2026 close; the EV/EBITDA column divides by operating profit before other income, so it reads higher than the Screener figures in the proxies table (25.8x for Poly), which include other income. The global device median is 13.7x EV/EBITDA (Mercer Capital, data to 31 Mar 2026). On the same operating-profit basis only Q-Line (14.1x) and Tarsons (16.5x) trade near that median, and both have weak earnings records, so the cheap multiple is not a free lunch.

What Rs 1,444 requires from Poly Medicure

Solving for one variable at a time and keeping the rest of my base case, the price asks for about twice the growth, or a discount rate far below the cost of capital, or a margin double today’s.

The solve keeps ten explicit years (FY27E to FY36E), tax at 25%, capital intensity from fixed-asset turns of 1.3x to 1.5x, net cash of Rs 501 cr (Rs 855 cr of cash and investments from the Q1 FY27 call less Rs 354 cr of borrowings), 10.14 crore shares from Screener’s market cap and price, and terminal growth of 5.5% at a 16% return on new capital. The 9.1% line is the cleanest way to read it: the price discounts Poly’s cash flows at barely two points above the 7% government bond rate, which is how a very safe compounder is priced, not a company with R&D at 1.6% of sales, 28% of revenue sold in India under price-control risk and renal lines under Chinese pricing pressure.

What a 12% return needs from earnings and the multiple

The table shows the price today that earns 12% a year for five years (before dividends), for a given annual EPS growth rate and exit P/E, starting from trailing EPS of Rs 31.09.

At Rs 1,444 the matching cell is about 16% EPS growth and a 40x exit multiple. My base case compounds EPS at 16.0% from FY26 to FY30E and Poly’s record since FY21 is 17.5%, so the growth is plausible; the 40x is the stretch, against a trailing P/E of 45.7x today and a global device median of 13.7x EV/EBITDA. To earn 12% a year at a lower 30x exit, EPS would have to compound about 22% a year; at a 25x exit it would need about 27%. Five turns of exit multiple and four points of annual EPS growth are each worth roughly Rs 180 to Rs 200 a share, and the multiple is the one management cannot influence.

Sum of the parts for Poly Medicure

Poly’s Q1 FY27 segment view is infusion 49%, orthopaedics 9%, renal 8% and cardiology 5%. The other 29% (blood management, surgery, anaesthesia and the rest) is not itemised in the figures I have, so I value it as other consumables. I apply that mix to FY27E revenue of Rs 2,300 cr, the bottom of the Rs 2,300 to 2,400 cr guidance. Margins and multiples are my assumptions, set against the 14x to 24x EV/EBITDA range of the larger Indian peers, Poly’s own forward multiple of about 27x at the current price, and the 13.7x global median.

The mid case is Rs 1,351 a share, 6% below the price. A low case (consumables 20x, renal 14x, orthopaedics 16x, cardiology 3.5x sales) gives Rs 1,084, and a high case (30x, 22x, 25x, 7x sales) gives Rs 1,629. The price sits inside that band but needs the consumables franchise to be worth about 25x forward EBITDA or more, in line with SMT’s 24.0x and well above Tarsons (16.5x) and Q-Line (14.1x). Cardiology adds Rs 575 cr, about Rs 57 a share or 4% of the price, so the market is paying for the existing infusion franchise, not for the pipeline.

What is priced in and what is not

For the price to earn 12% a year, several things must hold together: revenue near my base-case Rs 3,528 cr by FY30, EBITDA margin at 24% or better, an exit multiple still near 40x P/E, channel rules that stop short of ex-factory prices, and renal pricing that stabilises. Miss any one and nothing in the price absorbs it. At my base-case EPS growth and a 30x exit, the price that earns 12% is Rs 1,112, about 23% below today. This is analysis of what the price implies, not a recommendation to buy or sell; I am not a licensed adviser.

What to watch

The thesis breaks on price rules and on Poly’s execution before it breaks on demand, so the watch-list is built around the levels at which I would change my view. The thresholds are my judgement, not published targets.

Prices, market caps and ratios are from Screener.in at the 23 Oct 2026 close; the analysis was written on 24 Oct 2026. Forward figures are my assumptions and marked (E). This is research and analysis, not investment advice, and I am not a licensed adviser.

Sources

• IBEF, Medical Devices Industry in India
• India Briefing, PLI progress and 2026 outlook
• Trade.gov, India medical devices market intelligence
• IMARC, India Medical Devices Market
• Fortune Business Insights, global medical devices market
• Medical Buyer, domestic disposables and import dependence
• Medical Buyer, Centre reviews hospital consumable pricing after 2,841% markup finding
• Business Today, patients overpaying for life-saving devices (Apr 2026)
• Business Today, private hospitals capex (Jul 2026)
• Business Today, why India’s device manufacturing has seen limited success (Aug 2026)
• Mercer Capital, Medtech and Device Value Focus (data to 31 Mar 2026)
• Medtronic FY26 results release
• iData Research, medical device tariffs in 2026
• MedTech Dive, Section 232 roundup
• Investing.com, Poly Medicure Q1 FY27 slides
• IPO Watch, Sahajanand Medical Technologies
• InCred Money, SMT summary
• CARE Ratings, Meril Life Sciences India (Oct 2024)
• Screener.in company pages for POLYMED, SMT, MOLBIO, FISCHER, QLINE, TARSONS, LAXMIDENTL, Hemant Surgical, Vasa Denticity and APOLLOHOSP; Tijori Finance for Poly’s revenue mix and R&D intensity; Poly Medicure Q1 FY27 earnings call, 10 Aug 2026.

Also used: HDFC Securities initiation on Poly Medicure (May 2023), Medikabazaar on infusion-set construction, HMD needle brochure, GrowthJockey on supply-chain tiers and import dependence, the Department of Pharmaceuticals task force on diagnostics, and press coverage of the 2017 knee-implant cap.

Data as of 23 Oct 2026 (Screener.in close). I do not hold any of the stocks named here. This is research, not a recommendation to buy or sell, and I am not a licensed adviser; do your own research.